Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.11 USD | -2.29% | -3.45% | +9.45% |
Business Summary
Number of employees: 8
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Proprietary Medicinal Products
100.0
%
| 0 | nan % | 6 | 100.0 % | - |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 0 | nan % | 6 | 100.0 % | - |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Howard Berman
CEO | Chief Executive Officer | 50 | 31/12/19 |
Fred Grossman
PSD | President | 62 | 16/07/23 |
David Snyder
DFI | Director of Finance/CFO | 63 | 29/03/22 |
Michelle Frazier
LAW | General Counsel | - | 13/06/23 |
Arun Swaminathan
PRN | Corporate Officer/Principal | - | 26/03/23 |
John M. Centanni
LAW | General Counsel | - | 28/02/22 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Wilbur Ross
BRD | Director/Board Member | 85 | 12-18 |
Dov Goldstein
BRD | Director/Board Member | 56 | 13/04/21 |
Hideki Garren
BRD | Director/Board Member | 60 | 31/05/21 |
Dieter Weinand
BRD | Director/Board Member | 63 | 17/08/23 |
Director/Board Member | 65 | 24/05/21 | |
Ann Lee
BRD | Director/Board Member | 62 | 31/05/21 |
Howard Berman
CEO | Chief Executive Officer | 50 | 31/12/19 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 14,618,172 | 12,966,956 ( 88.70 %) | 0 | 88.70 % |
Company contact information
Coya Therapeutics, Inc.
5850 San Felipe Street Suite 500
77057, Houston
+
http://www.coyatherapeutics.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.45% | 123M | |
+64.23% | 62.59B | |
-2.31% | 41.18B | |
+45.43% | 40.29B | |
-8.29% | 27.9B | |
+11.97% | 26.21B | |
-21.16% | 19.09B | |
+7.54% | 13.08B | |
+27.17% | 12.05B | |
+25.72% | 12.26B |
- Stock Market
- Equities
- COYA Stock
- Company Coya Therapeutics, Inc.